全國服務(wù)咨詢熱線：
18438616290
18438616290
簡要描述：Radotinib 926037-48-1Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer
產(chǎn)品型號：abs47027997廠商性質(zhì)：生產(chǎn)廠家更新時(shí)間：2026-01-12訪 問 量：640產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 926037-48-1 |
|---|---|---|---|
| 分子式 | C27H21F3N8O | 純度 | 98% |
| 分子量 | 530.5 | 貨號 | abs47027997 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | a drug for the treatment of different ty | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Radotinib 926037-48-1
| 產(chǎn)品描述 | |
| 描述 | Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)[1] with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors |
| 純度 | 98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 拉多替尼; IY-5511 |
| 外觀 | Off white to light yellow powder |
| 可溶性/溶解性 | 10 mM in DMSO |
| 生物活性 | |
| 靶點(diǎn) | BCR-ABL1 |
| In vitro(體外研究) | In vitro, Radotinib binds BCR-ABL1 and reduces phosphorylation of CrkL, a BCR-ABL1 target protein. Radotinib also effectively inhibits the proliferation of common mutant clones of BCR-ABL1, with the exception of T315I. In AML cells, radotinib significantly decreases the cell viability, promotes differentiation, and induces CD11b expression and apoptosis. In NB4, THP-1, and Kasumi-1 cells, radotinib also induces CD11b expression, and decreases the viability. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | CancerOncoproteins/suppressorsOncoproteinsOther EpigeneticsTranscriptionCancer susceptibilityProto-oncogenes Signal TransductionProtein PhosphorylationTyrosine KinasesOther Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：